OBJECTIVE: To determine the lowest dosage of vaginally administered estradiol (E2) that reverses signs and symptoms of urogenital atrophy but does not substantially increase plasma E2 levels. DESIGN: Single-blind, single-arm study to determine the effects of de-escalating doses of vaginal estrogen on symptoms of urogenital atrophy, vaginal pH, and vaginal and urethral cytology. A questionnaire was used to assess subjective vaginal and urethral symptoms. Objective measurements included vaginal and urethral cytology, pH, endometrial biopsy, and 24-h circulating plasma luteinizing hormone, follicle-stimulating hormone (FSH), E2, and estrone levels obtained in a Clinical Research Unit. Circulating E2 levels were assayed with an ultrasensitive yeast bioassay with a detection limit of 0.02 pg/mL. Measurements were obtained over a 24-h period after administration of vehicle alone, on day 1 after the initial vaginal E2 dosage, after 3 weeks of daily E2 administration, and after an additional 9 weeks of twice weekly administration. RESULTS: From the first seven subjects studied at a 10-microg dose of E2, 100% responded according to predefined criteria. Vaginal cytology showed statistical improvement at 3 and 12 weeks. Urethral cytology was statistically improved after 12 weeks. Vaginal pH decreased from postmenopausal to premenopausal levels at both 3 and 12 weeks. Eighty-two percent of symptoms were cured or improved. Endometrium remained atrophic. Circulating E2 levels remained within the postmenopausal range of 3-10 pg/mL. CONCLUSION: A 10-microg dose of vaginal E2 effectively treated urogenital atrophy in seven women and did not cause endometrial hyperplasia or increase E2 levels.
OBJECTIVE: To determine the lowest dosage of vaginally administered estradiol (E2) that reverses signs and symptoms of urogenital atrophy but does not substantially increase plasma E2 levels. DESIGN: Single-blind, single-arm study to determine the effects of de-escalating doses of vaginal estrogen on symptoms of urogenital atrophy, vaginal pH, and vaginal and urethral cytology. A questionnaire was used to assess subjective vaginal and urethral symptoms. Objective measurements included vaginal and urethral cytology, pH, endometrial biopsy, and 24-h circulating plasma luteinizing hormone, follicle-stimulating hormone (FSH), E2, and estrone levels obtained in a Clinical Research Unit. Circulating E2 levels were assayed with an ultrasensitive yeast bioassay with a detection limit of 0.02 pg/mL. Measurements were obtained over a 24-h period after administration of vehicle alone, on day 1 after the initial vaginal E2 dosage, after 3 weeks of daily E2 administration, and after an additional 9 weeks of twice weekly administration. RESULTS: From the first seven subjects studied at a 10-microg dose of E2, 100% responded according to predefined criteria. Vaginal cytology showed statistical improvement at 3 and 12 weeks. Urethral cytology was statistically improved after 12 weeks. Vaginal pH decreased from postmenopausal to premenopausal levels at both 3 and 12 weeks. Eighty-two percent of symptoms were cured or improved. Endometrium remained atrophic. Circulating E2 levels remained within the postmenopausal range of 3-10 pg/mL. CONCLUSION: A 10-microg dose of vaginal E2 effectively treated urogenital atrophy in seven women and did not cause endometrial hyperplasia or increase E2 levels.
Authors: Shilpa N Bhupathiraju; Francine Grodstein; Meir J Stampfer; Walter C Willett; Carolyn J Crandall; Jan L Shifren; JoAnn E Manson Journal: Menopause Date: 2018-12-17 Impact factor: 2.953
Authors: Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian Journal: J Clin Endocrinol Metab Date: 2010-06-21 Impact factor: 5.958
Authors: Debra L Barton; Lynne T Shuster; Travis Dockter; Pamela J Atherton; Jacqueline Thielen; Stephen N Birrell; Richa Sood; Patricia Griffin; Shelby A Terstriep; Bassam Mattar; Jacqueline M Lafky; Charles L Loprinzi Journal: Support Care Cancer Date: 2017-11-21 Impact factor: 3.603
Authors: Rogerio A Lobo; Serge Bélisle; William T Creasman; Nancy R Frankel; Neil F Goodman; Janet E Hall; Susan Lee Ivey; Sheryl Kingsberg; Robert Langer; Rebecca Lehman; Donna Behler McArthur; Valerie Montgomery-Rice; Morris Notelovitz; Gary S Packin; Robert W Rebar; MaryEllen Rousseau; Robert S Schenken; Diane L Schneider; Katherine Sherif; Susan Wysocki Journal: MedGenMed Date: 2006
Authors: Gilbert Donders; Patrick Neven; Maximilian Moegele; Anneleen Lintermans; Gert Bellen; Valdas Prasauskas; Philipp Grob; Olaf Ortmann; Stefan Buchholz Journal: Breast Cancer Res Treat Date: 2014-04-10 Impact factor: 4.872